Results 21 to 30 of about 3,690 (206)
High-dose DFMO alters protein translation in neuroblastoma. [PDF]
NeoplasiaABSTRACT DFMO has been studied as a cancer therapeutic at doses ranging from 500-9,000 mg/m2/day. Lower doses are favored for cancer prevention studies while higher doses, often with chemotherapy, are studied in refractory cancers. DFMO inhibits the rate-limiting enzyme in polyamine synthesis, ornithine decarboxylase (
Franson AT +6 more
europepmc +4 more sources
Preclinical Evaluation of the Efficacy of α-Difluoromethylornithine and Sulindac Against SARS-CoV-2 Infection [PDF]
VirusesDespite numerous research efforts and several effective vaccines and therapies developed against coronavirus disease 2019 (COVID-19), drug repurposing remains an attractive alternative approach for treatment of SARS-CoV-2 variants and other viral ...
Natalia A. Ignatenko +6 more
doaj +2 more sources
Development of difluoromethylornithine (DFMO) as a chemoprevention agent. [PDF]
Clinical cancer research : an official journal of the American Association for Cancer Research, 1999 D,L-alpha-difluoromethylornithine (DFMO) was synthesized over 20 years ago. It was hoped that this enzyme-activated, irreversible inhibitor of ornithine decarboxylase, the first enzyme in polyamine synthesis, would be effective as a chemotherapy for ...
Meyskens, F L, Jr, Gerner, E W
core +3 more sources
Difluoromethylornithine (DFMO) and Neuroblastoma: A Review
Cureus, 2023 Neuroblastoma is a type of cancer that affects the sympathetic nervous system and is the most common extracranial solid tumor in children. Difluoromethylornithine (DFMO) is a drug that has shown promise as a treatment option for high-risk neuroblastoma.
Tangella, Adarsh Vardhan +3 more
openaire +2 more sources
Upregulation of Polyamine Transport in Human Colorectal Cancer Cells
Biomolecules, 2020 Polyamines are essential growth factors that have a positive role in cancer cell growth. Their metabolic pathway and the diverse enzymes involved have been studied in depth in multiple organisms and cells.
Misael Corral, Heather M. Wallace
doaj +1 more source
Characterising the Response of Human Breast Cancer Cells to Polyamine Modulation
Biomolecules, 2021 Breast cancer is a complex heterogeneous disease with multiple underlying causes. The polyamines putrescine, spermidine, and spermine are polycationic molecules essential for cell proliferation. Their biosynthesis is upregulated in breast cancer and they
Oluwaseun Akinyele, Heather M. Wallace
doaj +1 more source
DFMO: Targeted risk reduction therapy for colorectal neoplasia [PDF]
Best Practice & Research Clinical Gastroenterology, 2011 Strategies to decrease intracellular polyamine levels have been studied for their efficacy in reducing colorectal cancer (CRC) risk. A successful strategy combined agents that decreased polyamine synthesis by inhibiting ornithine decarboxylase with difluoromethylornithine (DFMO), and increased cellular export of polyamines by activating the spermidine ...
Christina M, Laukaitis, Eugene W, Gerner
openaire +2 more sources
Polyamine depletion induces G1 and S phase arrest in human retinoblastoma Y79 cells
Cancer Cell International, 2008 Background Polyamines and ornithine decarboxylase (ODC) are essential for cell proliferation. DL-α-difluoromethylornithine (DFMO), a synthetic inhibitor of ODC, induces G1 arrest through dephosphorylation of retinoblastoma protein (pRb).
Kubota Shunichiro +2 more
doaj +1 more source
The effects of DFMO on polyamine metabolism in the inner ear
Hearing Research, 1991 Difluoromethylornithine (DFMO) is a novel antineoplastic agent that was associated with an unexpected hearing loss in Phase II clinical trials. DFMO interferes with polyamine synthesis by inhibition of the enzyme ornithine decarboxylase (ODC). The objective of the current study was to establish a methodology to determine the effect of DFMO on polyamine
S C, Marks, D E, Mattox, R A, Casero
openaire +2 more sources
Cancer Reports, 2022 Background Survival for patients with high‐risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapies. Aims To study the feasibility and safety of incorporating a genomic‐based targeted agent to induction therapy for HRNB as well as ...
Jacqueline M. Kraveka +23 more
doaj +1 more source